Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT01345630
Registration number
NCT01345630
Ethics application status
Date submitted
27/04/2011
Date registered
2/05/2011
Date last updated
14/01/2016
Titles & IDs
Public title
Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With CCR5 Tropic HIV 1
Query!
Scientific title
A Multicenter, Randomized, Double-Blind, Comparative Trial Of Maraviroc + Darunavir/Ritonavir Versus Emtricitabine/Tenofovir + Darunavir/Ritonavir For The Treatment Of Antiretroviral-Naive Hiv-Infected Patients With Ccr5-Tropic Hiv-1
Query!
Secondary ID [1]
0
0
2010-021785-30
Query!
Secondary ID [2]
0
0
A4001095
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
MODERN
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
HIV-1
0
0
Query!
Condition category
Condition code
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Maraviroc
Treatment: Drugs - Emtricitabine/tenofovir
Treatment: Drugs - darunavir/ritonavir 800/100 mg
Treatment: Drugs - placebo for emtricitabine/tenofovir
Treatment: Drugs - placebo for maraviroc
Experimental: Maraviroc - Maraviroc 150 mg once daily plus darunavir/ritonavir 800/100 mg once daily plus placebo for emtricitabine/tenofovir once daily.
Active Comparator: Emtricitabine/tenofovir - Emtricitabine/tenofovir 200/300 mg once daily plus darunavir/ritonavir 800/100 mg once daily plus placebo for maraviroc once daily.
Treatment: Drugs: Maraviroc
Maraviroc tablet 150 mg once daily for 96 weeks.
Treatment: Drugs: Emtricitabine/tenofovir
Emtricitabine/tenofovir tablet 200/300 mg once daily for 96 weeks.
Treatment: Drugs: darunavir/ritonavir 800/100 mg
darunavir/ritonavir 800/100 mg
Treatment: Drugs: placebo for emtricitabine/tenofovir
placebo for emtricitabine/tenofovir
Treatment: Drugs: placebo for maraviroc
placebo for maraviroc
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Participants With Plasma HIV-1 RNA <50 Copies/mL.
Query!
Assessment method [1]
0
0
The proportion of participants who achieved HIV-1 RNA <50 copies/mL at week 48 was assessed according to Food and Drug Administration's (FDA's) Missing, Switch, Discontinuation'=Failure (MSDF) Snapshot algorithm. The algorithm used the plasma HIV-1 RNA in the Week 48 visit window, followed the "virology-first principle" and considers a participant who has a missing plasma HIV-1 RNA, or switches to prohibited ARV regimen or discontinues from the study or study drug for any reason, or dies, as a failure.
Query!
Timepoint [1]
0
0
Week 48
Query!
Secondary outcome [1]
0
0
Frequency of Adverse Events (AE).
Query!
Assessment method [1]
0
0
Number of participants with treatment-emergent non serious AEs
Query!
Timepoint [1]
0
0
Week 96
Query!
Secondary outcome [2]
0
0
Number of Participants With Grade 3 or 4 AEs
Query!
Assessment method [2]
0
0
Number of participants with grade 3 or 4 AEs are presented here.
Query!
Timepoint [2]
0
0
Week 96
Query!
Secondary outcome [3]
0
0
Number of Participants Who Discontinued Due to AEs
Query!
Assessment method [3]
0
0
Number of participants who discontinued due to AEs are reported here. Three participants (two from the MVC+DRV/r arm and one from the FTC/TDF+DRV/r arm) were not considered as discontinued due to AE because other reasons for discontinuation were prioritized for these participants.
Query!
Timepoint [3]
0
0
Week 96
Query!
Secondary outcome [4]
0
0
Number of Treatment-related AEs
Query!
Assessment method [4]
0
0
Number of treatment-related AEs are presented here.
Query!
Timepoint [4]
0
0
Week 96
Query!
Secondary outcome [5]
0
0
Number of Participants With Treatment-emergent Serious Adverse Events
Query!
Assessment method [5]
0
0
Total number of participants with treatment-emergent serious adverse events are reported
Query!
Timepoint [5]
0
0
Week 96
Query!
Secondary outcome [6]
0
0
Number of Participants With Abnormal Laboratory Values
Query!
Assessment method [6]
0
0
Number of participants with laboratory abnormalities are reported
Query!
Timepoint [6]
0
0
Week 96
Query!
Secondary outcome [7]
0
0
Severity of Abnormal Laboratory Values
Query!
Assessment method [7]
0
0
Number of participants who had clinically significant laboratory abnormalities of Grade 3 and Grade 4 according to DAIDS. Abnormality incidence of highest grade was reported for a labcode for each individual participant.
Query!
Timepoint [7]
0
0
Week 96
Query!
Secondary outcome [8]
0
0
The Relationship Between the Proportion of Participants With Plasma HIV-1 RNA <50 Copies/mL at the Week 48 and the Screening Tropism Test (Genotype Test or ESTA).
Query!
Assessment method [8]
0
0
The relationship of the proportion of participants achieving HIV-1 RNA <50 copies/mL at Week 48 with the screening tropism test for the MVC containing regimen was analyzed. Virologic response for a participant at Week 48 was derived using the FDA's Snapshot MSDF algorithm. Difference in proportions of patients with plasma HIV-1 RNA <50 copies/mL at week 48 between the maraviroc and the emtricitabine/tenofovir treatment arms, with two-sided 95% confidence interval, among patients who are R5 by genotype (including some who were originally randomized to ESTA and are R5 by genotype upon retesting), were calculated via the Maximum Likelihood method. The estimate was adjusted for the screening plasma HIV RNA level (<100,000 vs. =100,000) copies/mL via the Mantel Haenszel (MH) method.
Query!
Timepoint [8]
0
0
Week 48
Query!
Secondary outcome [9]
0
0
Virologic Outcomes at Week 48 Using Protocol-Defined Treatment Failure (PDTF).
Query!
Assessment method [9]
0
0
Per the protocol participants who meet the following criteria were regarded as PDTFs requiring a confirmatory plasma HIV-1 RNA determination: • Decrease in plasma HIV-1 RNA <1 log10 from baseline after Week 4 unless plasma HIV-1 RNA is <50 copies/mL, or • Plasma HIV-1 RNA >1.0 log10 above the nadir value after Week 4 where the nadir is the lowest plasma HIV-1 RNA concentration, or • Plasma HIV-1 RNA =50 copies/mL at any time after Week 24, or • Plasma HIV-1 RNA =50 copies/mL after suppression to <50 copies/mL on two consecutive visits, or • Decrease in plasma HIV-1 RNA =2 log10 from baseline on or after Week 12 unless plasma HIV-1 RNA is <400 copies/mL. Decrease in plasma HIV-1 RNA =2 log10 from baseline on or after Week 12 unless plasma HIV-1 RNA is <50 copies/mL (before August 30 2012) or <400 copies/mL (after August 30 2012).
Query!
Timepoint [9]
0
0
Week 48
Query!
Secondary outcome [10]
0
0
Tropism Change Between Screening or Baseline and PDTF
Query!
Assessment method [10]
0
0
For participants meeting the PDTF criteria, tropism was assessed using the original randomized and alternate assays (ie, both genotype testing and ESTA). Data reported here corresponds to the timepoint at or after PDTF.
Query!
Timepoint [10]
0
0
Week 48
Query!
Secondary outcome [11]
0
0
Number of Participants With Viral Resistance to Maraviroc (Maraviroc Treated Participants Only) in Participants Meeting PDTF Criteria.
Query!
Assessment method [11]
0
0
For participants meeting the PDTF criteria, viral resistance to maraviroc for maraviroc treated participants was assessed in patients with R5 virus at failure. The resistance level is calculated by reference to a laboratory strain of virus that is analyzed in parallel with the clinical isolate to identify 50% inhibitory concentrations (IC50). The maximal percent inhibition is the percent inhibition that is achieved in a titration of the drug at high concentrations when the addition of more drug does not result in increased inhibition. Maximal percent inhibition is obtained in the same way as the titration for IC50, but the key measure is of the plateau height of percent inhibition, where increased concentration of maraviroc does not result in additional inhibition. This is consistent with the virus developing some ability to use maraviroc-bound CCR5 for entry. A significant change in IC50 is not required for this mechanism.
Query!
Timepoint [11]
0
0
Week 48
Query!
Secondary outcome [12]
0
0
Number of Participants With Resistance to Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTI), Non-nucleoside Reverse Transcriptase Inhibitors (NNRTI), and Protease Inhibitors (PI) in Participants Meeting PDTF Criteria
Query!
Assessment method [12]
0
0
For participants meeting the PDTF criteria, viral resistance (both genotypic and phenotypic) to NRTI, NNRTI, and PI's were assessed at Baseline and on-treatment. The assessment was performed using the overall (i.e. net) susceptibility score provided using the PhenoSense GT assay. The number of participants with successful assessments were 15/17 for the MVC+DRV/r arm and 3/3 for the FTC/TDF+DRV/r arm.
Query!
Timepoint [12]
0
0
Week 48
Query!
Secondary outcome [13]
0
0
Absolute Change From Baseline in Immune Cell Function at Week 48: Lymphocyte Marker Cluster of Differentiation 4 (CD4, Cell/mm^3)
Query!
Assessment method [13]
0
0
The differences in the magnitude of changes in CD4+ at Baseline and at Week 48 for maraviroc versus emtricitabine/tenofovir were compared.
Query!
Timepoint [13]
0
0
Baseline, Week 48
Query!
Secondary outcome [14]
0
0
Percent Change From Baseline in Immune Cell Function at Week 48: Lymphocyte Activation Marker CD4 (%)
Query!
Assessment method [14]
0
0
The differences in the magnitude of changes in CD4+ from Baseline through Week 48 for maraviroc versus emtricitabine/tenofovir were compared.
Query!
Timepoint [14]
0
0
Baseline, Week 48
Query!
Secondary outcome [15]
0
0
Absolute Change From Baseline in Immune Cell Function at Week 48: Lymphocyte Marker Cluster of Differentiation 8 (CD8, Cell/mm^3)
Query!
Assessment method [15]
0
0
The differences in the magnitude of changes in CD8+ cell counts from baseline through Week 48 for maraviroc versus emtricitabine/tenofovir were compared.
Query!
Timepoint [15]
0
0
Baseline, Week 48
Query!
Secondary outcome [16]
0
0
Percent Change From Baseline in Immune Cell Function at Week 48: Lymphocyte Activation Marker CD8 (%)
Query!
Assessment method [16]
0
0
The differences in the magnitude of changes in CD8+ cell counts from Baseline through Week 48 for maraviroc versus emtricitabine/tenofovir were compared.
Query!
Timepoint [16]
0
0
Baseline, Week 48
Query!
Secondary outcome [17]
0
0
Absolute Change in CD4+/CD8+ Ratio From Baseline to Week 48
Query!
Assessment method [17]
0
0
The differences in the magnitude of changes in CD4+/CD8+ ratio from Baseline through Weeks 48 for maraviroc versus emtricitabine/tenofovir were compared.
Query!
Timepoint [17]
0
0
Baseline, Week 48
Query!
Secondary outcome [18]
0
0
Changes in Peripheral Fat Distribution Using Dual Energy X-ray Absorptiometry [DEXA] Scan From Baseline and at Week 48.
Query!
Assessment method [18]
0
0
A sub-study was conducted in which the participants underwent whole-body DEXA scans to evaluate peripheral fat tissue estimates for left and right arms and legs and truncal fat mass and truncal lean mass. Truncal abdominal fat were estimated from the DEXA scan field set on the torso. The effects on estimates of fat mass and lean mass were addressed by providing LSMs of change from baseline.
Query!
Timepoint [18]
0
0
Week 48
Query!
Secondary outcome [19]
0
0
Changes in Trunk to Limb Fat Distribution Using DEXA Scan From Baseline and at Week 48
Query!
Assessment method [19]
0
0
A sub-study was conducted in which the participants underwent whole-body DEXA scans to evaluate peripheral fat tissue estimates for left and right arms and legs and truncal fat mass and truncal lean mass. Truncal abdominal fat were estimated from the DEXA scan field set on the torso. The effects on estimates of fat mass and lean mass were addressed by providing LSMs of change from baseline.
Query!
Timepoint [19]
0
0
Week 48
Query!
Secondary outcome [20]
0
0
Changes in Bone Mineral Density (Using DEXA Scan and Serum Markers) From Baseline and at Week 48 - Total Hip BMD
Query!
Assessment method [20]
0
0
Bone mineral density was evaluated by DEXA scan in a subset of participants who consented to these evaluations. The effects on BMD were addressed by providing LSMs of change from baseline bone mineral density of the lumbar spine (L1-L4), left total hip and femoral neck as measured by the DEXA scan.
Query!
Timepoint [20]
0
0
Week 48
Query!
Secondary outcome [21]
0
0
Changes in Bone Mineral Density (Using DEXA Scan and Serum Markers) From Baseline and at Week 48 - Femoral Neck BMD
Query!
Assessment method [21]
0
0
Bone mineral density was evaluated by DEXA scan in a subset of participants who consented to these evaluations. The effects on BMD were addressed by providing LSMs of change from Baseline bone mineral density femoral neck as measured by the DEXA scan.
Query!
Timepoint [21]
0
0
Week 48
Query!
Secondary outcome [22]
0
0
Changes in Bone Mineral Density (Using DEXA Scan and Serum Markers) From Baseline and at Week 48 - AP Lumbar Spine (L1 - L4) BMD
Query!
Assessment method [22]
0
0
Bone mineral density was evaluated by DEXA scan in a subset of participants who consented to these evaluations. The effects on BMD were addressed by providing LSMs of change from baseline bone mineral density of the lumbar spine (L1-L4) as measured by the DEXA scan.
Query!
Timepoint [22]
0
0
Week 48
Query!
Secondary outcome [23]
0
0
Change in Bone Turnover Markers From Baseline and at Week 48 - Blood Osteocalcin
Query!
Assessment method [23]
0
0
Bone turnover marker, osteocalcin, was collected in the subset of participants participating in the DEXA scan sub-study.
Query!
Timepoint [23]
0
0
Week 48
Query!
Secondary outcome [24]
0
0
Change in Bone Turnover Markers From Baseline and at Week 48 - Type 1 Collagen Peptide (CTX-1)
Query!
Assessment method [24]
0
0
Bone turnover marker, C-telopeptide of type 1 collagen (CTx), was collected in the subset of participants participating in the DEXA scan sub-study.
Query!
Timepoint [24]
0
0
Week 48
Query!
Eligibility
Key inclusion criteria
- Plasma HIV-1 RNA equal to or greater than 1,000 copies/mL measured at the Screening
Visit.
- CD4 count equal to or greater than 100 cells/mm3 at Screening.
- Have only R5 HIV 1 at Screening as verified by a randomized tropism assay.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Prior treatment with any other HIV antiretroviral therapy for more than 14 days at any
time.
- Any evidence of genotypic/phenotypic resistance to darunavir, tenofovir, and
emtricitabine.
- CXCR4 using virus detected using randomized tropism determination or repeated failure
to obtain an interpretable tropism result.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Terminated
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/09/2011
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/01/2014
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
813
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Query!
Recruitment hospital [1]
0
0
East Sydney Doctors - Darlinghurst
Query!
Recruitment hospital [2]
0
0
Holdsworth House General Practice - Darlinghurst
Query!
Recruitment hospital [3]
0
0
St Vincent's Hospital - Darlinghurst
Query!
Recruitment hospital [4]
0
0
Taylor Square Private Clinic - Surry Hills
Query!
Recruitment hospital [5]
0
0
Brisbane Sexual Health and HIV Service - Brisbane
Query!
Recruitment hospital [6]
0
0
Melbourne Sexual Health Centre - Carlton
Query!
Recruitment hospital [7]
0
0
Clinical Research Unit, Infectious Diseases - Melbourne
Query!
Recruitment postcode(s) [1]
0
0
2010 - Darlinghurst
Query!
Recruitment postcode(s) [2]
0
0
2010 - Surry Hills
Query!
Recruitment postcode(s) [3]
0
0
4000 - Brisbane
Query!
Recruitment postcode(s) [4]
0
0
3053 - Carlton
Query!
Recruitment postcode(s) [5]
0
0
3004 - Melbourne
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Colorado
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Connecticut
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
District of Columbia
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Florida
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Georgia
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Illinois
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Iowa
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Louisiana
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Massachusetts
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Michigan
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Minnesota
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Missouri
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Nebraska
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
New Jersey
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
New York
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
North Carolina
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Ohio
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Texas
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Washington
Query!
Country [22]
0
0
Austria
Query!
State/province [22]
0
0
Wien
Query!
Country [23]
0
0
Belgium
Query!
State/province [23]
0
0
Antwerpen
Query!
Country [24]
0
0
Belgium
Query!
State/province [24]
0
0
Brussels
Query!
Country [25]
0
0
Belgium
Query!
State/province [25]
0
0
Bruxelles
Query!
Country [26]
0
0
Belgium
Query!
State/province [26]
0
0
Gent
Query!
Country [27]
0
0
Belgium
Query!
State/province [27]
0
0
Liege
Query!
Country [28]
0
0
Canada
Query!
State/province [28]
0
0
British Columbia
Query!
Country [29]
0
0
Canada
Query!
State/province [29]
0
0
Ontario
Query!
Country [30]
0
0
Canada
Query!
State/province [30]
0
0
Quebec
Query!
Country [31]
0
0
Denmark
Query!
State/province [31]
0
0
Hvidovre
Query!
Country [32]
0
0
Denmark
Query!
State/province [32]
0
0
Koebenhavn OE
Query!
Country [33]
0
0
Denmark
Query!
State/province [33]
0
0
Odense
Query!
Country [34]
0
0
Finland
Query!
State/province [34]
0
0
Helsinki
Query!
Country [35]
0
0
France
Query!
State/province [35]
0
0
Cedex 02
Query!
Country [36]
0
0
France
Query!
State/province [36]
0
0
Cedex 12
Query!
Country [37]
0
0
France
Query!
State/province [37]
0
0
Cedex 18
Query!
Country [38]
0
0
France
Query!
State/province [38]
0
0
Bordeaux cedex
Query!
Country [39]
0
0
France
Query!
State/province [39]
0
0
Creteil
Query!
Country [40]
0
0
France
Query!
State/province [40]
0
0
Le Kremlin Bicetre
Query!
Country [41]
0
0
France
Query!
State/province [41]
0
0
LYON Cedex 4
Query!
Country [42]
0
0
France
Query!
State/province [42]
0
0
Montpellier
Query!
Country [43]
0
0
France
Query!
State/province [43]
0
0
Nantes
Query!
Country [44]
0
0
France
Query!
State/province [44]
0
0
Paris Cedex 10
Query!
Country [45]
0
0
France
Query!
State/province [45]
0
0
Paris
Query!
Country [46]
0
0
France
Query!
State/province [46]
0
0
Strasbourg Cedex
Query!
Country [47]
0
0
France
Query!
State/province [47]
0
0
Tourcoing
Query!
Country [48]
0
0
Germany
Query!
State/province [48]
0
0
Berlin
Query!
Country [49]
0
0
Germany
Query!
State/province [49]
0
0
Bonn
Query!
Country [50]
0
0
Germany
Query!
State/province [50]
0
0
Frankfurt am Main
Query!
Country [51]
0
0
Germany
Query!
State/province [51]
0
0
Hamburg
Query!
Country [52]
0
0
Germany
Query!
State/province [52]
0
0
Koeln
Query!
Country [53]
0
0
Germany
Query!
State/province [53]
0
0
Muenchen
Query!
Country [54]
0
0
Hungary
Query!
State/province [54]
0
0
Budapest
Query!
Country [55]
0
0
Italy
Query!
State/province [55]
0
0
Milano
Query!
Country [56]
0
0
Netherlands
Query!
State/province [56]
0
0
Utrecht
Query!
Country [57]
0
0
Poland
Query!
State/province [57]
0
0
Bydgoszcz
Query!
Country [58]
0
0
Poland
Query!
State/province [58]
0
0
Warszawa
Query!
Country [59]
0
0
Poland
Query!
State/province [59]
0
0
Wroclaw
Query!
Country [60]
0
0
Portugal
Query!
State/province [60]
0
0
Amadora
Query!
Country [61]
0
0
Portugal
Query!
State/province [61]
0
0
Lisboa
Query!
Country [62]
0
0
Portugal
Query!
State/province [62]
0
0
Porto
Query!
Country [63]
0
0
Puerto Rico
Query!
State/province [63]
0
0
Bayamon
Query!
Country [64]
0
0
Puerto Rico
Query!
State/province [64]
0
0
Ponce
Query!
Country [65]
0
0
Puerto Rico
Query!
State/province [65]
0
0
Rio Piedras
Query!
Country [66]
0
0
Puerto Rico
Query!
State/province [66]
0
0
San Juan
Query!
Country [67]
0
0
Spain
Query!
State/province [67]
0
0
Barcelona
Query!
Country [68]
0
0
Spain
Query!
State/province [68]
0
0
Alicante
Query!
Country [69]
0
0
Spain
Query!
State/province [69]
0
0
Cordoba
Query!
Country [70]
0
0
Spain
Query!
State/province [70]
0
0
Madrid
Query!
Country [71]
0
0
Spain
Query!
State/province [71]
0
0
Sevilla
Query!
Country [72]
0
0
Sweden
Query!
State/province [72]
0
0
Goteborg
Query!
Country [73]
0
0
Sweden
Query!
State/province [73]
0
0
Malmo
Query!
Country [74]
0
0
Sweden
Query!
State/province [74]
0
0
Stockholm
Query!
Country [75]
0
0
Switzerland
Query!
State/province [75]
0
0
Basel
Query!
Country [76]
0
0
Switzerland
Query!
State/province [76]
0
0
Bern
Query!
Country [77]
0
0
Switzerland
Query!
State/province [77]
0
0
St. Gallen
Query!
Country [78]
0
0
Switzerland
Query!
State/province [78]
0
0
Zurich
Query!
Country [79]
0
0
United Kingdom
Query!
State/province [79]
0
0
Birmingham
Query!
Country [80]
0
0
United Kingdom
Query!
State/province [80]
0
0
Brighton
Query!
Country [81]
0
0
United Kingdom
Query!
State/province [81]
0
0
Edinburgh
Query!
Country [82]
0
0
United Kingdom
Query!
State/province [82]
0
0
London
Query!
Country [83]
0
0
United Kingdom
Query!
State/province [83]
0
0
Manchester
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
ViiV Healthcare
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/Industry
Query!
Name [1]
0
0
Pfizer
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to assess whether maraviroc administered once daily is
non-inferior to emtricitabine/tenofovir also administered once daily each in combination with
darunavir/ritonavir in the treatment of antiretroviral-naive patients as evaluated at Week 48
of treatment.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT01345630
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Pfizer CT.gov Call Center
Query!
Address
0
0
Pfizer
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT01345630
Download to PDF